https://www.selleckchem.com/products/jdq443.html
BACKGROUND Emerging evidence supports a role of the receptor activator of nuclear factor κB (RANK) pathway in mammary gland development and breast carcinogenesis. Osteoprotegerin (OPG) is the endogenous decoy receptor for RANK-ligand (RANKL) that inhibits RANK-signaling. Whether OPG may be a biomarker of breast cancer risk remains unclear. METHODS We evaluated the association between plasma OPG and breast cancer risk in a case (n=297)-control (n=297) study nested within the Nurses' Health Study II. Cases were cancer-free and premenopausa
Synes godt om
Kommentar
Del
